摘要
目的观察在不同农度脂多糖(LPS)作用下,大蒜素对人牙周膜成纤维细胞(hPDLCs)炎症因子及MMP-1表达的影响c方法建立hPDLCs有限细胞系,将梯度浓度LPS作用于第5代hPDLCs 48 h,观察组培养液加入6μg/ml大蒜素作用48 h,对照组加入等量培养液。采用ELISA法检测各组培养液中IL-1β、TNF-α、MMP-1的分泌量。结果对照组随着LPS浓度的增高,TNF-α、IL-1β及MMP-1的表达呈增高趋势(P<0.05)。观察组在0.1μg/mlLPS作用下,6μg/ml大蒜素组与未添加大蒜素组比较,TNF-α、IL-1P差异无统计学意义(P>0.05);在1 pg/ml、10μg/mlLPS作用下,6 pg/ml大蒜素组与未添加大蒜素组比较,TNF-α、IL-1β及MMP-1均有下降(P<0.05);10 pg/mlLPS作用下6μg/ml大蒜素对IL-1β、TNF-α、MMP-1分泌抑制率高于1μg/ml LPS作用下6μg/ml大蒜素对三者的分泌抑制率c结论大蒜素可显著降低LPS诱导hPDLCs分泌炎症因子及MMP-1的作用,对中重度牙周炎可能具有更好的抗炎及抗基质降解作用。
Objective To observe the effect of allicin on the expression of inflammatory factors and MMP-1 in human periodontal ligament fibroblasts(hPDLCs)under the action of different concentrations oflipopolysaccharide(LPS).Methods A limited hPDLCs cell line was established,the 5th generation hPDLCs were treated with gradient concentrations of LPS for 48 h,6μg/ml allicin was added to the culture medium of the observation group for 48 hours,and the control group was added the same amount of culture medium.ELISA was used to detect the secretion of IL-1β,TNF-αand MMP-1 in the two cultures.Results In the control group,with the increase of LPS concentration,the expression of TNF-α,IL-1βand MMP-1 showed an increasing trend(P<0.05).In the observation group under the action of 0.1μg/ml LPS,the 6μg/ml allicin group was compared with the non-allicin group,there was no significant difference in TNF-αand IL-1β(P>0.05);at 1μg/ml,Under the action of 10μg/ml LPS,TNF-α,IL-1βand MMP-1 decreased in the 6 g/ml allicin group compared with the group without allicin(P<0.05);under the action of 10μg/ml LPS The inhibition rate of 6μg/ml allicin on the secretion of IL-1β,TNF-α.and MMP-1 was higher than that of 6μg/ml allicin on the secretion of the three under the action of 1μg/ml LPS.Conclusion Allicin can significantly reduce the effect of LPS-induced hPDLCs to secrete inflammatory factors and MMP-1,and may have better anti-inflammatory and anti-matrix degradation effects on moderate to severe periodontitis.
出处
《浙江临床医学》
2021年第6期821-823,共3页
Zhejiang Clinical Medical Journal
基金
温州市科技计划项目(Y2020966)。